ADAM17 regulates IL-1 signaling by selectively releasing IL-1 receptor type 2 from the cell surface

Cytokine

Volumn 71, Issue 2, 2015, Pages 238-245

  Uchikawa, Shinichi ^a   Yoda, Masaki ^a   Tohmonda, Takahide ^a   Kanaji, Arihiko ^a   Matsumoto, Morio ^a   Toyama, Yoshiaki ^a   Horiuchi, Keisuke ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

ADAM17 TACE; Ectodomain shedding; IL 1 receptors

Indexed keywords

INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR TYPE I; INTERLEUKIN 1 RECEPTOR TYPE II; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME; ADAM PROTEIN; IL1R1 PROTEIN, MOUSE; PHORBOL 13 ACETATE 12 MYRISTATE; TUMOR NECROSIS FACTOR-ALPHA CONVERTASE;

AMINO ACID SEQUENCE; ANIMAL CELL; ARTICLE; CELL CULTURE; CELL SURFACE; CONTROLLED STUDY; FLOW CYTOMETRY; GENETIC TRANSFECTION; MOLECULAR CLONING; MOUSE; MUTATION; NONHUMAN; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN SECRETION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; ANIMAL; ANIMAL EMBRYO; BINDING SITE; CHLOROCEBUS AETHIOPS; COS 1 CELL LINE; CYTOLOGY; DRUG EFFECTS; FIBROBLAST; GENETICS; KNOCKOUT MOUSE; METABOLISM; MOLECULAR GENETICS; SEQUENCE HOMOLOGY; WESTERN BLOTTING;

ADAM PROTEINS; AMINO ACID SEQUENCE; ANIMALS; BINDING SITES; BLOTTING, WESTERN; CELLS, CULTURED; CERCOPITHECUS AETHIOPS; COS CELLS; EMBRYO, MAMMALIAN; FIBROBLASTS; INTERLEUKIN-1; MICE, KNOCKOUT; MOLECULAR SEQUENCE DATA; PROTEOLYSIS; RECEPTORS, INTERLEUKIN-1 TYPE I; RECEPTORS, INTERLEUKIN-1 TYPE II; SEQUENCE HOMOLOGY, AMINO ACID; SIGNAL TRANSDUCTION; TETRADECANOYLPHORBOL ACETATE;

EID: 84911418559     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2014.10.032     Document Type: Article

References (42)

1. Dinarello C.A. Blocking IL-1 in systemic inflammation. J Exp Med 2005, 201:1355-1359.
2. Dinarello C.A. Immunological and inflammatory functions of the interleukin-1 family. Annu Rev Immunol 2009, 27:519-550.
3. Sims J.E., Smith D.E. The IL-1 family: regulators of immunity. Nat Rev Immunol 2010, 10:89-102.
4. Dinarello C.A. Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood 2011, 117:3720-3732.
5. Garlanda C., Dinarello C.A., Mantovani A. The interleukin-1 family: back to the future. Immunity 2013, 39:1003-1018.
6. O'Neill L.A. The interleukin-1 receptor/toll-like receptor superfamily: 10 years of progress. Immunol Rev 2008, 226:10-18.
7. Cullinan E.B., Kwee L., Nunes P., Shuster D.J., Ju G., McIntyre K.W., et al. IL-1 receptor accessory protein is an essential component of the IL-1 receptor. J Immunol 1998, 161:5614-5620.
8. Lang D., Knop J., Wesche H., Raffetseder U., Kurrle R., Boraschi D., et al. The type II IL-1 receptor interacts with the IL-1 receptor accessory protein: a novel mechanism of regulation of IL-1 responsiveness. J Immunol 1998, 161:6871-6877.
9. Re F., Sironi M., Muzio M., Matteucci C., Introna M., Orlando S., et al. Inhibition of interleukin-1 responsiveness by type II receptor gene transfer: a surface "receptor" with anti-interleukin-1 function. J Exp Med 1996, 183:1841-1850.
10. Colotta F., Re F., Muzio M., Bertini R., Polentarutti N., Sironi M., et al. Interleukin-1 type II receptor: a decoy target for IL-1 that is regulated by IL-4. Science 1993, 261:472-475.
11. Rauschmayr T., Groves R.W., Kupper T.S. Keratinocyte expression of the type 2 interleukin 1 receptor mediates local and specific inhibition of interleukin 1-mediated inflammation. Proc Natl Acad Sci USA 1997, 94:5814-5819.
12. Mantovani A., Locati M., Vecchi A., Sozzani S., Allavena P. Decoy receptors: a strategy to regulate inflammatory cytokines and chemokines. Trends Immunol 2001, 22:328-336.
13. Symons J.A., Young P.R., Duff G.W. Soluble type II interleukin 1 (IL-1) receptor binds and blocks processing of IL-1 beta precursor and loses affinity for IL-1 receptor antagonist. Proc Natl Acad Sci 1995, 92:1714-1718.
14. Martin P., Palmer G., Vigne S., Lamacchia C., Rodriguez E., Talabot-Ayer D., et al. Mouse neutrophils express the decoy type 2 interleukin-1 receptor (IL-1R2) constitutively and in acute inflammatory conditions. J Leukoc Biol 2013, 94:791-802.
15. Reddy P., Slack J.L., Davis R., Cerretti D.P., Kozlosky C.J., Blanton R.A., et al. Functional analysis of the domain structure of tumor necrosis factor-alpha converting enzyme. J Biol Chem 2000, 275:14608-14614.
16. Orlando S., Sironi M., Bianchi G., Drummond A.H., Boraschi D., Yabes D., et al. Role of metalloproteases in the release of the IL-1 type II decoy receptor. J Biol Chem 1997, 272:31764-31769.
17. Lorenzen I., Lokau J., Dusterhoft S., Trad A., Garbers C., Scheller J., et al. The membrane-proximal domain of a disintegrin and metalloprotease 17 (ADAM17) is responsible for recognition of the interleukin-6 receptor and interleukin-1 receptor II. FEBS Lett 2012, 586:1093-1100.
18. Black R.A., Rauch C.T., Kozlosky C.J., Peschon J.J., Slack J.L., Wolfson M.F., et al. A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature 1997, 385:729-733.
19. Moss M.L., Jin S.L., Milla M.E., Bickett D.M., Burkhart W., Carter H.L., et al. Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-alpha. Nature 1997, 385:733-736.
20. Murphy G. The ADAMs: signalling scissors in the tumour microenvironment. Nat Rev Cancer 2008, 8:929-941.
21. Murphy G., Murthy A., Khokha R. Clipping, shedding and RIPping keep immunity on cue. Trends Immunol 2008, 29:75-82.
22. Scheller J., Chalaris A., Garbers C., Rose-John S. ADAM17: a molecular switch to control inflammation and tissue regeneration. Trends Immunol 2011, 32:380-387.
23. Horiuchi K. A brief history of tumor necrosis factor alpha-converting enzyme: an overview of ectodomain shedding. Keio J Med 2013, 62:29-36.
24. Horiuchi K., Kimura T., Miyamoto T., Takaishi H., Okada Y., Toyama Y., et al. TNFalpha-converting enzyme (TACE/ADAM17) inactivation in mouse myeloid cells prevents lethality from endotoxin shock. J Immunol 2007, 179:2686-2689.
25. Chalaris A., Rabe B., Paliga K., Lange H., Laskay T., Fielding C.A., et al. Apoptosis is a natural stimulus of IL6R shedding and contributes to the proinflammatory trans-signaling function of neutrophils. Blood 2007, 110:1748-1755.
26. Yoda M., Kimura T., Tohmonda T., Uchikawa S., Koba T., Takito J., et al. Dual functions of cell-autonomous and non-cell-autonomous ADAM10 activity in granulopoiesis. Blood 2011, 118:6939-6942.
27. Horiuchi K., Morioka H., Takaishi H., Akiyama H., Blobel C.P., Toyama Y. Ectodomain shedding of FLT3 ligand is mediated by TNF-alpha converting enzyme. J Immunol 2009, 182:7408-7414.
28. Horiuchi K., Le Gall S., Schulte M., Yamaguchi T., Reiss K., Murphy G., et al. Substrate selectivity of epidermal growth factor-receptor ligand sheddases and their regulation by phorbol esters and calcium influx. Mol Biol Cell 2007, 18:176-188.
29. Morita S., Kojima T., Kitamura T., Plat E. An efficient and stable system for transient packaging of retroviruses. Gene Ther 2000, 7:1063-1066.
30. Orlando S., Polentarutti N., Mantovani A. Selectivity release of the type II decoy IL-1 receptor. Cytokine 2000, 12:1001-1006.
31. Baker A.H., Edwards D.R., Murphy G. Metalloproteinase inhibitors: biological actions and therapeutic opportunities. J Cell Sci 2002, 115:3719-3727.
32. Lambert E., Dasse E., Haye B., Petitfrere E. TIMPs as multifacial proteins. Crit Rev Oncol Hematol 2004, 49:187-198.
33. Peschon J.J., Slack J.L., Reddy P., Stocking K.L., Sunnarborg S.W., Lee D.C., et al. An essential role for ectodomain shedding in mammalian development. Science 1998, 282:1281-1284.
34. Harris R.C., Chung E., Coffey R.J. EGF receptor ligands. Exp Cell Res 2003, 284:2-13.
35. Sahin U., Weskamp G., Kelly K., Zhou H.M., Higashiyama S., Peschon J., et al. Distinct roles for ADAM10 and ADAM17 in ectodomain shedding of six EGFR ligands. J Cell Biol 2004, 164:769-779.
36. Weber A., Wasiliew P., Kracht M. Interleukin-1 (IL-1) pathway. Sci Signa 2010, 3:cm1.
37. Neumann D., Kollewe C., Martin M.U., Boraschi D. The membrane form of the type II IL-1 receptor accounts for inhibitory function. J Immunol 2000, 165:3350-3357.
38. Briso E.M., Dienz O., Rincon M. Cutting edge: soluble IL-6R is produced by IL-6R ectodomain shedding in activated CD4 T cells. J Immunol 2008, 180:7102-7106.
39. Solomon K.A., Pesti N., Wu G., Newton R.C. Cutting edge: a dominant negative form of TNF-alpha converting enzyme inhibits proTNF and TNFRII secretion. J Immunol 1999, 163:4105-4108.
40. Re F., Muzio M., De Rossi M., Polentarutti N., Giri J.G., Mantovani A., et al. The type II "receptor" as a decoy target for interleukin 1 in polymorphonuclear leukocytes: characterization of induction by dexamethasone and ligand binding properties of the released decoy receptor. J Exp Med 1994, 179:739-743.
41. Zheng Y., Humphry M., Maguire J.J., Bennett M.R., Clarke M.C. Intracellular interleukin-1 receptor 2 binding prevents cleavage and activity of interleukin-1alpha, controlling necrosis-induced sterile inflammation. Immunity 2013, 38:285-295.
42. Horai R., Saijo S., Tanioka H., Nakae S., Sudo K., Okahara A., et al. Development of chronic inflammatory arthropathy resembling rheumatoid arthritis in interleukin 1 receptor antagonist-deficient mice. J Exp Med 2000, 191:313-320.